Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2025 07:01 ET | Source: AbbVie Canada

L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne

SKYRIZI®, un inhibiteur de l’interleukine 23 (IL-23), a fait l’objet de deux recommandations consécutives de l’Agence des médicaments du Canada (AMC) visant son remboursement pour le traitement des...
November 28, 2025 07:01 ET | Source: AbbVie Canada

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s...
November 27, 2025 08:19 ET | Source: Research and Markets

TL1A Inhibitors & DR3 Antagonists Competitor Analysis Report 2025: A Focus on Innovative Bispecific and Trispecific Antibodies, Alongside Expanding R&D in Targeted Therapies

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
November 20, 2025 06:16 ET | Source: Research and Markets

Inflammatory Bowel Disease Treatment Market Analysis Report 2025-2033: Adoption of MAb, Biosimilars, Targeted Therapies is Reshaping Patient Management and Improving Outcomes

Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
November 19, 2025 10:32 ET | Source: Research and Markets

Gastrointestinal Collaboration and Licensing Agreements Analysis Report and Directory 2019-2025: Upfront, Milestone, and Royalties by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Gastrointestinal Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
November 19, 2025 10:22 ET | Source: Research and Markets

Pouchitis Market Research and Forecast Report 2025-2035: Takeda, Ocera Therapeutics, Exegi Pharma, and Atlantic Pharmaceuticals Lead Through Innovation, Partnerships, and Product Diversification

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Pouchitis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
November 19, 2025 10:22 ET | Source: Research and Markets

Necrotizing Enterocolitis Market Research and Forecast Report 2025-2035: Increasing R&D Investments in Microbiome Modulation, Immunotherapy, and Novel Biologics are Opening New Avenues

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Necrotizing Enterocolitis Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnosis, End User, Country, and Region - Analysis and...
November 17, 2025 08:30 ET | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity

Woburn, MA, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two...
November 06, 2025 10:48 ET | Source: Research and Markets

U.S. Colon Screening Market and Company Analysis Report, 2025-2033 - Insurance and Government Policies Drive Participation in Colon Screening

Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "United States Colon Screening Market Report by Type, End Use, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's...
November 06, 2025 09:00 ET | Source: Vibrant Gastro

New Real-World Evidence Study Demonstrates Vibrant System’s Continuous Effectiveness and Exceptional Tolerability for Chronic Idiopathic Constipation

Austin, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vibrant Gastro announced today the publication of new real-world evidence in Clinical and Translational Gastroenterology demonstrating the long-term...